0

Heparin Market by Product, Route of Administration, and Geography - Forecast and Analysis 2021-2025

  • Published: Aug 2021
  • Pages: 120
  • SKU: IRTNTR40831
Technavio

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The heparin market share is expected to increase by USD 2.29 billion from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 6.06%.

This heparin market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers heparin market segmentations by product (low-molecular-weight heparin and others), route of administration (subcutaneous injection and intravenous/infusion) and geography (Europe, North America, Asia, and ROW). The heparin market report also offers information on several market vendors, including Aspen Pharmacare Holdings Ltd., Baxter International Inc., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi SA, Nanjing Kingfriend Biochemical Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi SA, and Viatris Inc. among others.

What will the Heparin Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Heparin Market Size for the Forecast Period and Other Important Statistics

 

Heparin Market: Key Drivers, Trends, and Challenges

The increasing prevalence of coagulation disorders is notably driving the heparin market growth, although factors such as may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the heparin industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Heparin Market Driver

The increasing prevalence of coagulation disorders is a major factor driving the global heparin market share growth. The prevalence of various coagulation disorders, such as Von Willebrand disease, hemophilia, deep venous thrombosis, hypercoagulable states, and clotting factor deficiencies, is increasing significantly across the world. For instance, according to the data published by the CDC in July 2020, nearly 400 babies are born with hemophilia A every year in the US. In addition, according to the data stated by the CDC in February 2020, nearly 900,000 people in the US are affected by venous thromboembolism, also known as DVT/PE, every year. The increasing prevalence of various coagulation disorders among people around the world requires continuous monitoring for further medical interventions. Furthermore, coagulation tests are recommended by physicians during major surgeries. This, in turn, is driving the growth of the global heparin market.

Key Heparin Market Trend

The increasing R&D activities and new therapeutic applications of heparin are other factors supporting the global heparin market share growth. In recent years, it has been identified that heparin exhibits anti-inflammatory activities and prevents the metastatic spread of tumor cells. Owing to such properties of heparin, researchers are now focusing on investigating heparin for other indications. For instance, heparin has been tested in controlled clinical trials as a treatment for adult respiratory distress syndrome. Recommended mechanisms include a reduction in the activation and growth of cells in airways and the neutralization of mediators and toxins in cells. Animal models have shown that heparin could improve lung functions. Similarly, according to researchers, molecular studies of heparin suggest that it may have beneficial effects as an arthritis treatment. Furthermore, the non-anticoagulant activity of heparin on metastasis includes the ability to inhibit cell interaction through blocking P- and L-selectin. This inhibits extracellular matrix protease heparanase and angiogenesis. Further studies are being conducted to explore the use of heparin in the metastatic spread of tumor cells. These factors are likely to support the growth of the global heparin market during the forecast period.

Key Heparin Market Challenge

The side effects of heparin will be a major challenge for the global heparin market share growth during the forecast period. Heparin was first used to prevent the clotting of blood in vitro. Currently, it has been clinically used to treat thrombosis. However, the side effects associated with the use of heparin to treat thrombosis are high. Bleeding is the primary adverse effect of heparin. The other main adverse effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, skin reactions, eosinophilia, and allergic reactions. Among the above-mentioned side effects, heparin-induced thrombocytopenia and osteoporosis are quite common. The market is witnessing a decrease in the use of heparin because of its strong side effects. The increasing awareness of the side effects of heparin is expected to hinder the growth of the global heparin market.

This heparin market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the global heparin market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the heparin market during the forecast period.

Who are the Major Heparin Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • Aspen Pharmacare Holdings Ltd.
  • Baxter International Inc.
  • Eisai Co. Ltd.
  • Fresenius SE and Co. KGaA
  • Hikma Pharmaceuticals Plc
  • Laboratorios Farmaceuticos Rovi SA
  • Nanjing Kingfriend Biochemical Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Viatris Inc.

 

This statistical study of the heparin market encompasses successful business strategies deployed by the key vendors. The heparin market is fragmented and the vendors are deploying growth strategies such as forming strategic alliances to expand their product portfolio to compete in the market.

Product Insights and News

  • Aspen Pharmacare Holdings Ltd.- The company offers Fraxiparine which is an anticoagulant belonging to a class of drugs called low-molecular-weight heparins. It is used in general and orthopedic surgery to prevent thromboembolic disorders and treatment for deep vein thrombosis.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The heparin market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Heparin Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the heparin market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the global pharmaceuticals market includes the following core components:

  • Inputs
  • Inbound logistics
  • Operations
  • Outbound logistics
  • Marketing and sales
  • Service
  • Support activities
  • Innovation

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

 

Which are the Key Regions for Heparin Market?

For more insights on the market share of various regions Request for a FREE sample now!

37% of the market’s growth will originate from Europe during the forecast period. UK, Germany, and France are the key markets for the heparin market in Europe. Market growth in this region will be faster than the growth of the market in North America and ROW.

The increasing prevalence of obesity, smoking, and the high consumption of alcohol will facilitate the heparin market growth in Europe over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The prevalence of COVID-19 in European countries has led to an increase in the demand for heparin for the effective treatment of patients with severe symptoms of COVID-19 to reduce the chances of mortality. This, in turn, is propelling the growth of the heparin market in Europe. Furthermore, the geriatric population is increasing significantly in Europe. The geriatric population is at a high risk of developing several coagulation diseases, which increases the demand for heparin for better diagnosis to save lives. Moreover, the ongoing COVID-19 pandemic has become a serious healthcare emergency, with the UK and Italy being the worst-hit countries in the region. The pandemic significantly amplified the demand for heparin, as elevated D-dimer levels positively correlate with mortality in COVID-19 patients. This is expected to drive the demand for heparin during this pandemic, as the requirement for anticoagulant treatment in patients suffering from COVID-19-induced thrombosis is high. This, in turn, is fostering the growth of the heparin market in Europe, which will continue during the forecast period.

What are the Revenue-generating Product Segments in the Heparin Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The heparin market share growth in the low-molecular-weight heparin segment will be significant during the forecast period. Owing to the wide availability of low-molecular-weight heparin products and their advantages and efficacy, their adoption is expected to grow during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the heparin market size and actionable market insights on post COVID-19 impact on each segment.

 

Heparin Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 6.06%

Market growth 2021-2025

$ 2.29 billion

Market structure

Fragmented

YoY growth (%)

5.75

Regional analysis

Europe, North America, Asia, and ROW

Performing market contribution

Europe at 37%

Key consumer countries

US, UK, Germany, China, and France

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Aspen Pharmacare Holdings Ltd., Baxter International Inc., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi SA, Nanjing Kingfriend Biochemical Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi SA, and Viatris Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Heparin Market Report?

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive heparin market growth during the next five years
  • Precise estimation of the heparin market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the heparin industry across Europe, North America, Asia, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of heparin market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

1 Executive Summary

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 01: Parent market
    • Exhibit 02: Market characteristics
  • 2.2 Value chain analysis
    • Exhibit 03: Value chain analysis: Pharmaceuticals

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 04: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 05: Market segments
  • 3.3 Market size 2020
    • 3.4 Market outlook: Forecast for 2020 - 2025
      • Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
      • Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)

    4 Five Forces Analysis

    • 4.1 Five forces analysis
      • Exhibit 08: Five forces analysis 2020 & 2025
    • 4.2 Bargaining power of buyers
      • Exhibit 09: Bargaining power of buyers
    • 4.3 Bargaining power of suppliers
      • Exhibit 10: Bargaining power of suppliers
    • 4.4 Threat of new entrants
      • Exhibit 11: Threat of new entrants
    • 4.5 Threat of substitutes
      • Exhibit 12: Threat of substitutes
    • 4.6 Threat of rivalry
      • Exhibit 13: Threat of rivalry
    • 4.7 Market condition
      • Exhibit 14: Market condition - Five forces 2020

    5 Market Segmentation by Product

    • 5.1 Market segments
      • Exhibit 15: Product - Market share 2020-2025 (%)
    • 5.2 Comparison by Product
      • Exhibit 16: Comparison by Product
    • 5.3 Low-molecular-weight heparin - Market size and forecast 2020-2025
      • Exhibit 17: Low-molecular-weight heparin - Market size and forecast 2020-2025 ($ million)
    • 5.4 Low-molecular-weight heparin
      • Exhibit 18: Low-molecular-weight heparin - Year-over-year growth 2020-2025 (%)
    • 5.5 Others - Market size and forecast 2020-2025
      • Exhibit 19: Others - Market size and forecast 2020-2025 ($ million)
      • Exhibit 20: Others - Year-over-year growth 2020-2025 (%)
    • 5.6 Market opportunity by Product
      • Exhibit 21: Market opportunity by Product

    6 Market Segmentation by Route of administration

    • 6.1 Market segments
      • Exhibit 22: Route of administration - Market share 2020-2025 (%)
    • 6.2 Comparison by Route of administration
      • Exhibit 23: Comparison by Route of administration
    • 6.3 Subcutaneous injection - Market size and forecast 2020-2025
      • Exhibit 24: Subcutaneous injection - Market size and forecast 2020-2025 ($ million)
      • Exhibit 25: Subcutaneous injection - Year-over-year growth 2020-2025 (%)
    • 6.4 Intravenous/infusion - Market size and forecast 2020-2025
      • Exhibit 26: Intravenous/infusion - Market size and forecast 2020-2025 ($ million)
      • Exhibit 27: Intravenous/infusion - Year-over-year growth 2020-2025 (%)
    • 6.5 Market opportunity by Route of administration
      • Exhibit 28: Market opportunity by Route of administration

    7 Customer landscape

    • 7.1 Customer landscape
      • Exhibit 29: Customer landscape

    8 Geographic Landscape

    • 8.1 Geographic segmentation
      • Exhibit 30: Market share by geography 2020-2025 (%)
    • 8.2 Geographic comparison
      • Exhibit 31: Geographic comparison
    • 8.3 Europe - Market size and forecast 2020-2025
      • Exhibit 32: Europe - Market size and forecast 2020-2025 ($ million)
      • Exhibit 33: Europe - Year-over-year growth 2020-2025 (%)
    • 8.4 North America - Market size and forecast 2020-2025
      • Exhibit 34: North America - Market size and forecast 2020-2025 ($ million)
      • Exhibit 35: North America - Year-over-year growth 2020-2025 (%)
    • 8.5 Asia - Market size and forecast 2020-2025
      • Exhibit 36: Asia - Market size and forecast 2020-2025 ($ million)
      • Exhibit 37: Asia - Year-over-year growth 2020-2025 (%)
    • 8.6 ROW - Market size and forecast 2020-2025
      • Exhibit 38: ROW - Market size and forecast 2020-2025 ($ million)
      • Exhibit 39: ROW - Year-over-year growth 2020-2025 (%)
    • 8.7 Key leading countries
      • Exhibit 40: Key leading countries
    • 8.8 Market opportunity by geography
      • Exhibit 41: Market opportunity by geography ($ million)

    9 Drivers, Challenges, and Trends

    • 9.1 Market drivers
      • 9.2 Market challenges
        • Exhibit 42: Impact of drivers and challenges
      • 9.3 Market trends

        10 Vendor Landscape

        • 10.1 Overview
          • Exhibit 43: Vendor landscape
        • 10.2 Landscape disruption

          11 Vendor Analysis

          • 11.1 Vendors covered
            • Exhibit 46: Vendors covered
          • 11.2 Market positioning of vendors
            • Exhibit 47: Market positioning of vendors
          • 11.3 Aspen Pharmacare Holdings Ltd.
            • Exhibit 48: Aspen Pharmacare Holdings Ltd. - Overview
            • Exhibit 49: Aspen Pharmacare Holdings Ltd. - Business segments
            • Exhibit 50: Aspen Pharmacare Holdings Ltd.- Key news
            • Exhibit 51: Aspen Pharmacare Holdings Ltd. - Key offerings
            • Exhibit 52: Aspen Pharmacare Holdings Ltd. - Segment focus
          • 11.4 Baxter International Inc.
            • Exhibit 53: Baxter International Inc. - Overview
            • Exhibit 54: Baxter International Inc. - Business segments
            • Exhibit 55: Baxter International Inc. - Key offerings
            • Exhibit 56: Baxter International Inc. - Segment focus
          • 11.5 Eisai Co. Ltd.
            • Exhibit 57: Eisai Co. Ltd. - Overview
            • Exhibit 58: Eisai Co. Ltd. - Business segments
            • Exhibit 59: Eisai Co. Ltd. - Key offerings
            • Exhibit 60: Eisai Co. Ltd. - Segment focus
          • 11.6 Fresenius SE and Co. KGaA
            • Exhibit 61: Fresenius SE and Co. KGaA - Overview
            • Exhibit 62: Fresenius SE and Co. KGaA - Business segments
            • Exhibit 63: Fresenius SE and Co. KGaA - Key offerings
            • Exhibit 64: Fresenius SE and Co. KGaA - Segment focus
          • 11.7 Hikma Pharmaceuticals Plc
            • Exhibit 65: Hikma Pharmaceuticals Plc - Overview
            • Exhibit 66: Hikma Pharmaceuticals Plc - Business segments
            • Exhibit 67: Hikma Pharmaceuticals Plc - Key news
            • Exhibit 68: Hikma Pharmaceuticals Plc - Key offerings
            • Exhibit 69: Hikma Pharmaceuticals Plc - Segment focus
          • 11.8 Laboratorios Farmaceuticos Rovi SA
            • Exhibit 70: Laboratorios Farmaceuticos Rovi SA - Overview
            • Exhibit 71: Laboratorios Farmaceuticos Rovi SA - Business segments
            • Exhibit 72: Laboratorios Farmaceuticos Rovi SA - Key offerings
            • Exhibit 73: Laboratorios Farmaceuticos Rovi SA - Segment focus
          • 11.9 Nanjing Kingfriend Biochemical Pharmaceutical Co. Ltd.
            • Exhibit 74: Nanjing Kingfriend Biochemical Pharmaceutical Co. Ltd. - Overview
            • Exhibit 75: Nanjing Kingfriend Biochemical Pharmaceutical Co. Ltd. - Product and service
            • Exhibit 76: Nanjing Kingfriend Biochemical Pharmaceutical Co. Ltd. - Key offerings
          • 11.10 Pfizer Inc.
            • Exhibit 77: Pfizer Inc. - Overview
            • Exhibit 78: Pfizer Inc. - Business segments
            • Exhibit 79: Pfizer Inc. - Key news
            • Exhibit 80: Pfizer Inc. - Key offerings
            • Exhibit 81: Pfizer Inc. - Segment focus
          • 11.11 Sanofi SA
            • Exhibit 82: Sanofi SA - Overview
            • Exhibit 83: Sanofi SA - Business segments
            • Exhibit 84: Sanofi SA.- Key news
            • Exhibit 85: Sanofi SA - Key offerings
            • Exhibit 86: Sanofi SA - Segment focus
          • 11.12 Viatris Inc.
            • Exhibit 87: Viatris Inc. - Overview
            • Exhibit 88: Viatris Inc. - Business segments
            • Exhibit 89: Viatris Inc. - Key news
            • Exhibit 90: Viatris Inc. - Key offerings
            • Exhibit 91: Viatris Inc. - Segment focus

          12 Appendix

          • 12.1 Scope of the report
            • 12.2 Currency conversion rates for US$
              • Exhibit 92: Currency conversion rates for US$
            • 12.3 Research methodology
              • Exhibit 93: Research Methodology
              • Exhibit 94: Validation techniques employed for market sizing
              • Exhibit 95: Information sources
            • 12.4 List of abbreviations
              • Exhibit 96: List of abbreviations

            Research Framework

            Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

            TechnavioINFORMATION SOURCES

            Primary sources

            • Manufacturers and suppliers
            • Channel partners
            • Industry experts
            • Strategic decision makers

            Secondary sources

            • Industry journals and periodicals
            • Government data
            • Financial reports of key industry players
            • Historical data
            • Press releases
            Technavio

            TechnavioDATA ANALYSIS

            Data Synthesis

            • Collation of data
            • Estimation of key figures
            • Analysis of derived insights

            Data Validation

            • Triangulation with data models
            • Reference against proprietary databases
            • Corroboration with industry experts
            Technavio

            TechnavioREPORT WRITING

            Qualitative

            • Market drivers
            • Market challenges
            • Market trends
            • Five forces analysis

            Quantitative

            • Market size and forecast
            • Market segmentation
            • Geographical insights
            • Competitive landscape
            Interested in this report?
            Get your FREE sample now!
            The heparin market growth will increase by $2294.78 million during 2021-2025.
            The heparin market is expected to grow at a CAGR of 6.06% during 2021-2025.
            Technavio has segmented the heparin market by product (Low-molecular-weight heparin and Others) ,other1 (Subcutaneous injection and Intravenous/infusion) , and geographic (Europe, North America, Asia, and ROW).
            Aspen Pharmacare Holdings Ltd., Baxter International Inc., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi SA, Nanjing Kingfriend Biochemical Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi SA, Viatris Inc. are a few of the key vendors in the heparin market.
            Europe will register the highest growth rate of 36.67% among the other regions. Therefore, the heparin market in Europe is expected to garner significant business opportunities for the vendors during the forecast period.
            • US
            • UK
            • Germany
            • China
            • France
            The key factors driving the heparin market growth are:
            • Increasing prevalence of coagulation disorders
            The heparin market vendors should focus on grabbing business opportunities from the low-molecular-weight heparin segment as it accounted for the largest market share in the base year.
            Safe and Secure SSL Encrypted
            Technavio

            Single User:

            2500 USD

            Technavio Get the report (PDF) sent to your email within minutes.

            Subscribe & Save

            Get lifetime access to our
            Technavio Insights

            Want to customize this report?

            This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

            We offer $1000 worth of FREE customization at the time of purchase
            Technavio
            Enquire Before Buying
            1. Home
            2. Health Care
            3. Published Report
            17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>